Articles
Page 16 of 25
-
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A104
-
C-type natriuretic peptide/guanylyl cyclase-B (GC-B) system attenuates proliferation of rhabdomyosarcoma in combination with sildenafil: A novel anticancer therapy
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A103 -
Functional evaluation of GUCY1A3 mutations associated with myocardial infarction risk
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A100 -
Differences in the renal antifibrotic signaling of serelaxin and zaprinast
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A99 -
Real-time imaging of cGMP signals in platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A98 -
Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A97 -
Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A94 -
Natriuretic peptides, via GC-A/cGMP, moderate hypoxia-induced VEGF release from astrocytes and thereby pathological neovascularization in the retina
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A89 -
cIMP: Synthesis, effector activation, inactivation and occurrence in biological systems
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A85 -
Effects of obesity on sGCβ1 mediated signaling in white adipose tissue
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A83 -
Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A82 -
Age, noise and cGMP: Pharmacological activation of soluble guanylyl cyclase (sGC) interacts with the progression of age related and noise induced hearing loss
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A81 -
Evaluating a possible role for PKG1α redox state in chronic hypoxia-induced pulmonary hypertension
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A80 -
Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A79 -
C-type natriuretic peptide prevents angiotensin II-induced cardiac remodelling and dysfunction
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A78 -
Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A77 -
Asymmetric properties of rod cGMP Phosphodiesterase 6 (PDE6): structural and functional analysis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A76 -
NMR study of a soluble Guanylate Cyclase (sGC) human homologue: the H-NOX domain from Nostoc sp.
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A73 -
Natriuretic peptides regulate sympathetic nervous activity independent of mineralocorticoid receptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A71 -
Identification and characterization of small molecular NPR-B receptor antagonists
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A70 -
Comparative analysis of established and new biosensors for cyclic nucleotides
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A68 -
Contribution of the NO-GC isoforms to airway responsiveness
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A67 -
Rational design of a PKA-based sensor for cGMP
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A64 -
Correlation of vascular smooth muscle cell phenotype and cGMP signalling
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A63 -
The NO-cGMP pathway participates in vascular adaptation to oxidative stress in Nrf2 KO mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A62 -
CNP attenuates renal toxicity induced by cisplatin in murine kidney
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A61 -
Discovery of IWP-051, a Novel Orally Bioavailable Soluble Guanylate Cyclase Stimulator with Sustained and Dose-Dependent Hemodynamic Effects
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A59 -
NO-dependent cGMP signalling in neurons and astrocytes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A55 -
Cyclic GMP signaling and mitochondrial BK channels in cardioprotection against ischemia/reperfusion injury
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A50 -
A CNP-cGMP-cGKI-MAPK pathway promotes melanoma growth in vitro and in vivo in mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A49 -
Catalytically active guanylyl cyclase-B requires glycosylation and mutations that inhibit this process cause dwarfism
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A44 -
Investigating the impact of a mutation in PDE5A on myocardial infarction
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A43 -
Nitrosopersulfide (SSNO-) targets soluble guanylyl cyclase and induces vasodilation in vivo
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A42 -
C-type natriuretic peptide prevents activation of perivascular mast cells and inflammation in the postischemic microvasculature
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A41 -
The predator odor 2,4,5-trimethylthiazoline binds and activates receptor guanylyl cyclase-G to elicit innate defensive responses
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A40 -
Inhaled Nitric Oxide: an sGC-dependent IOP lowering agent
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A38 -
Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A37 -
Computational exploration of the binding mode of the heme-dependent activator YC-1 into the active catalytic site of soluble guanylate cyclase
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A32 -
Receptor guanylyl cyclase-G is a sensory protein activated by cool temperatures and predator odor 2,4,5-trimethylthiazoline
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A29 -
sGC redox regulation and asthma
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A26 -
Novel roles of cardiac natriuretic peptides in renal compensatory hypertrophy
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A22 -
Ultrasensitive signal detection by a guanylyl cyclase chemoreceptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A20 -
Targeting cyclic nucleotides in CNS drug discovery: a translational approach into cognition enhancement
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A18 -
New insights into leveraging PKG signalling to treat diseased hearts
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A17 -
Structural basis of cyclic nucleotide selectivity in cGMP dependent protein kinase II
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A15 -
Cyclic GMP/cGMP-dependent protein kinase type I signaling and cysteine-rich LIM-only protein 4 in AngII/AT1R-induced heart hypertrophy and fibrosis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A13 -
Soluble guanylyl cyclase regulates skeletal muscle fiber type plasticity, fatigue resistance and whole body insulin resistance
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A8 -
MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A3 -
The clinical development of sGC modulators, riociguat and vericiguat
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A2 -
LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A1
Annual Journal Metrics
-
2022 Citation Impact
2.9 - 2-year Impact Factor
2.9 - 5-year Impact Factor
0.932 - SNIP (Source Normalized Impact per Paper)
0.603 - SJR (SCImago Journal Rank)2023 Speed
57 days submission to first editorial decision for all manuscripts (Median)
178 days submission to accept (Median)2023 Usage
790,731 downloads
400 Altmetric mentions
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication